GRI Bio Inc. (GRI)
NASDAQ: GRI
· Real-Time Price · USD
2.10
0.15 (7.69%)
At close: May 02, 2025, 3:59 PM
2.08
-0.95%
Pre-market: May 05, 2025, 04:20 AM EDT
7.69% (1D)
| Bid | 2.1 |
| Market Cap | 1.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.21M |
| EPS (ttm) | -55.19 |
| PE Ratio (ttm) | -0.04 |
| Forward PE | -0.17 |
| Analyst | Strong Buy |
| Ask | 2.15 |
| Volume | 737,664 |
| Avg. Volume (20D) | 360,841 |
| Open | 1.98 |
| Previous Close | 1.95 |
| Day's Range | 1.88 - 2.43 |
| 52-Week Range | 1.10 - 106.08 |
| Beta | -2.38 |
About GRI
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sc...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 10, 2021
Employees 3
Stock Exchange NASDAQ
Ticker Symbol GRI
Website https://www.gribio.com
Analyst Forecast
According to 2 analyst ratings, the average rating for GRI stock is "Strong Buy." The 12-month stock price forecast is $115.5, which is an increase of 5400.00% from the latest price.
Stock Forecasts1 month ago
-36.88%
GRI Bio shares are trading lower after the company...
Unlock content with
Pro Subscription
2 months ago
-4.45%
GRI Bio shares are trading lower after the company announced a 1-for-17 reverse stock split.
